Supersolids are strange materials that behave like both a solid and a fluid due to quantum effects – and now researchers have created an intriguing new type of supersolid from laser light.
For decades, exercise was considered an optional part of cancer care—something beneficial for general health but not essential. The evidence is now overwhelming: exercise is not just supportive—it’s a therapeutic intervention that recalibrates tumor biology, enhances treatment tolerance, and improves survival outcomes.
With over 600 peer-reviewed studies, Dr. Kerry Courneya’s work has fundamentally reshaped our understanding of how structured exercise—whether aerobic, resistance training, or high-intensity intervals—can mitigate treatment side effects, enhance immune function, and directly influence cancer progression.
Train smarter with evidence-based strategies from top experts—get your free copy of “How to Train According to the Experts” at https://howtotrainguide.com/
CHAPTERS:
00:00:00 Introduction.
00:01:47 Why exercise should be effortful.
00:02:33 How to meaningfully reduce risk of cancer.
00:06:22 What type of exercise is best?
00:07:59 How exercise reduces risk—even for smokers and the obese.
00:10:48 Weekend-only exercise.
00:13:49 150 vs. 300 minutes per week (more is better—up to a point)
00:16:03 Why pre-diagnosis exercise matters.
00:19:09 Why resilience to cancer treatment starts with exercise.
00:21:01 Why low muscle mass drives cancer death.
00:23:58 Why BMI fails to measure true obesity.
00:27:51 Why daily activity isn’t enough (structured exercise matters)
00:29:34 Breaking up sedentary time—do ‘exercise snacks’ help?
00:31:50 Supplements vs. exercise.
00:32:32 Where exercise fits with chemo and immunotherapy.
00:35:30 Why rest is not the best medicine.
00:41:20 Aerobic vs. resistance.
00:42:11 How chemotherapy patients were able to put on over a kilogram of muscle.
00:42:13 How weight training improves ‘chemo completion’
00:44:41 Why exercise creates vulnerability in cancer cells (limitations do apply)
00:47:09 Why exercise might be crucial for tumor elimination.
00:53:03 Why cardio may be better at clearing tumor cells.
00:56:18 When cancer spreads quickly—and when it doesn’t.
00:57:43 Why liquid biopsies may prevent over-treatment.
01:02:56 Exercise-sensitive vs. exercise-resistant cancers.
01:06:06 Prostate cancer therapy—why strength training matters.
01:08:10 When exercise is the only therapy—does it work?
01:09:26 Why HIIT reduces PSA in prostate cancer.
01:11:40 Avoiding over-treatment—can exercise buy you time?
01:12:00 Why high-intensity exercise boosts anti-cancer biology.
01:13:11 Turning a diagnosis into a wake-up call.
01:16:11 Why oncologists are rethinking exercise.
01:18:50 Why exercise eases anxiety about cancer—proven psychological benefits.
01:25:00 Before, during, and after treatment.
01:27:02 Why exercise is unique among cancer therapies.
01:28:16 Why cancer patients stop exercising—the risky mistake almost everyone makes.
01:30:41 How to get sedentary cancer patients exercising (realistically)
01:33:15 The $1 million case for including exercise.
01:34:56 Why recurrence trials haven’t convinced doctors—yet.
01:37:36 The bottom-line message.
01:37:55 The myth of a cancer panacea (exercise included)
01:44:07 What’s the best $50 investment for staying active?
01:44:40 Only 15 minutes per day—what’s the best anti-cancer exercise?
A quick cautionary note: Always consult a qualified healthcare provider—presumably an oncologist if your questions involve cancer treatment—particularly if you’re considering actions based on or inspired by our conversation today. This episode should not be construed as a substitute for qualified medical advice.
*Kerry Courneya, PhD*
PBS Member Stations rely on viewers like you. To support your local station, go to: http://to.pbs.org/DonateSPACE
Sign Up on Patreon to get access to the Space Time Discord!
/ pbsspacetime.
Physics is the business of figuring out the structure of the world. So are our brains. But sometimes physics comes to conclusions that are in direct conflict with concepts fundamental to our minds, such as the realness of space and time. How do we tell who’s correct? Are time and space objective realities or human-invented concepts?
Episode Companion Playlist.
• What If Space And Time Are NOT Real?…
Check out the Space Time Merch Store.
https://www.pbsspacetime.com/shop.
Hydrogen energy promises a clean and sustainable future, but its production often depends on expensive platinum-based catalysts, making it costly. The industry needs more affordable alternatives to platinum to make hydrogen energy more viable.
Researchers from the Tokyo University of Science (TUS) have developed a new catalyst called bis(diimino)palladium coordination nanosheets (PdDI). These low-cost palladium-based nanosheets match platinum’s performance in producing hydrogen.
France just achieved a nuclear fusion breakthrough, making limitless energy virtually inevitable.
In a major achievement, France’s WEST Tokamak reactor has maintained a plasma reaction for over 22 minutes, setting a new world record in the quest for sustainable fusion energy.
énergie atomique et aux énergies alternatives (CEA), the experiment surpassed China’s previous record of 1,066 seconds, reaching 1,337 seconds of sustained plasma. + This milestone is a major step toward commercial fusion power, which promises unlimited, clean energy by harnessing the same process that powers the Sun. The challenge lies in achieving a self-sustaining reaction while maintaining extreme temperatures of up to 150 million°C (270 million°F) without damaging reactor components.
While WEST itself won’t become a commercial reactor, the data gathered will be instrumental in developing ITER, the world’s largest fusion project, currently under construction in southern France.
CEA scientists plan to extend reaction times further, increasing power levels and plasma stability. If successful, these advancements could bring humanity closer to realizing the long-held dream of clean, virtually limitless energy, potentially transforming global power generation in the future.
Learn more.
An amyloid protein targeted by Alzheimer’s disease therapies seems to be involved in normal mental decline.
Researchers across 14 medical centers in China, including Peking University People’s Hospital, have found that an investigational drug, berberine ursodeoxycholate (HTD1801), significantly lowered blood sugar levels and improved metabolic and liver health in patients with type 2 diabetes (T2D). The findings and an invited commentary, both published in JAMA Network Open, suggest that HTD1801 could serve as a new oral treatment option for T2D and its related complications.
Research suggests that free-moving panels on aircraft wings can improve stability, reduce turbulence, and add fuel efficiency.
In this work, I present a coherent and comprehensive argument for the nature of consciousness as the inherent ground of phenomena backed by experimental evidence confirming the predictions make by this hypothesis.
This argument makes its point by establishing an equivalence between all observers, generating a set of observational and mathematical predictions which were then tested and confirmed.
Furthermore, when the core tenet of the argument is accepted, it provides clear, testable explanations for most of the curently unresolved questions regarding consciousness, intelligence, and the nature of observed phenomena.
An arms race is unfolding in our cells: Transposons, also known as jumping genes or mobile genetic elements as they can replicate and reinsert themselves in the genome, threaten the cell’s genome integrity by triggering DNA rearrangements and causing mutations. Host cells, in turn, protect their genome using intricate defense mechanisms that stop transposons from jumping.
Now, for the first time, a retrotransposon has been caught in action inside a cell: Refining cryo-Electron Tomography (cryo-ET) techniques, scientists imaged the retrotransposon copia in the egg chambers of the fruitfly Drosophila melanogaster at sub-nanometer resolution. The paper is published in the journal Cell.
Among the international team of scientists achieving this detailed visualization are three scientists with Vienna BioCenter ties: Sven Klumpe, currently in the laboratory of Jürgen Plitzko at the Max Planck Institute of Biochemistry in Martinsried, will join IMBA and IMP to build a group as a Joint Fellow; Julius Brennecke, a Senior Group Leader at IMBA, the Institute of Molecular Biotechnology of the Austrian Academy of Sciences; and Kirsten Senti, staff scientist in the Brennecke group. Also involved in this collaboration is the group of Martin Beck at the Max Planck Institute of Biophysics in Frankfurt.